Quick Search:

is currently disabled due to reindexing of the ZORA database. Please use Advanced Search.
uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive 

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-63205

Daud, A; Soon, C; Dummer, R; Eggermont, A M M; Hwu, W J; Grob, J J; Garbe, C; Hauschild, A (2012). Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma. Expert Opinion on Biological Therapy, 12(8):1087-1099.

[img]Published Version
PDF - Registered users only
457kB

Abstract

Introduction: Both native IFNα2b and pegylated IFNα2b (PegIFNα2b) are approved for the adjuvant treatment of high-risk melanoma.

Areas covered: This review compares the toxicity profiles of high-dose IFNα2b (HDI) and PegIFNα2b, and provides recommendations on the management of common PegIFNα2b-related toxicities, based on available clinical data and published literature.

Expert opinion: The toxicity profile of PegIFNα2b at the approved dose (6 μg/kg/week for 8 weeks then 3 μg/kg/week for up to 5 years) is qualitatively similar to HDI in melanoma. The most common adverse events (AEs) are fatigue, anorexia, hepatotoxicity, flu-like symptoms, injection site reactions and depression. However, fatigue and flu-like symptoms appear less severe with PegIFNα2b, and toxicity seems to occur earlier, whereas with HDI toxicity may increase with time. Most AEs can be managed effectively by dose modification and aggressive symptom control. Dosing to tolerance using a three-step dose reduction schedule to maintain an ECOG performance status of 0 − 1 may enable patients experiencing toxicity to remain on treatment; this can be applied readily in clinical practice. PegIFNα2b is therefore a valuable alternative option for adjuvant treatment in melanoma, with a toxicity profile similar to that of HDI overall but a more convenient administration schedule.

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic
DDC:610 Medicine & health
Date:2012
Deposited On:02 Jul 2012 10:30
Last Modified:16 Jan 2014 18:12
Publisher:Informa Healthcare
ISSN:1471-2598
Publisher DOI:10.1517/14712598.2012.694421
PubMed ID:22694288
Citations:Web of Science®. Times Cited: 4
Google Scholar™
Scopus®. Citation Count: 4

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page